Before the Pathology Report: Pre-analytical Factors Affecting Biomarker Accuracy in Breast Cancer
In breast cancer, the pathology report does more than confirm malignancy: estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 proliferation index results guide treatment selection. The increasing therapeutic relevance of low levels of HER2 expression makes reliable tissue handling especially important. Four preventable failures threaten biomarker accuracy: surgical specimens left unfixed in the operating room; specimens from late-Friday or weekend surgery held without a defined pathology pathway; delayed handling of large specimens, including late dissection and inadequate fixation (intact immersion in insufficient formalin); and surgery performed without advance notification to the pathology laboratory. This narrative review integrates evidence on how cold ischemia, fixation conditions, and specimen logistics affect biomarker assessment, with particular attention to breast cancer care in Brazil. It proposes a practical checklist assigning responsibility for specimen identification, transfer, fixation, documentation, and communication. Although biomarker accuracy depends on multiple factors, protecting it begins immediately after excision and requires coordinated surgical and pathology workflows, including a defined after-hours pathway and documentation of excision and fixation times.
Authors
- Clóvis Klock (ORCID: https://orcid.org/0000-0001-8456-0061)
- Julia Grossi Diaz
- Julia C Monteiro Klock
- Lara C Ferreira
- Manuela Sousa
- Mariana Hassan Choucair
- Ana Carolina R Ferraz
- Barbara Paroneto
- Fernanda Beatriz F Pinto
Publication Details
- Journal
- Cureus
- Published
- 2026-11-21
- DOI
- https://doi.org/10.7759/cureus.120033
- Primary Topic
- Clinical Laboratory Practices and Quality Control
- Type
- article
- Field-Weighted Citation Impact
- 0.00